Printer Friendly

ALLIANCE PHARMACEUTICAL CORP. REPORTS RESULTS /FOLLOWING IS REPEAT OF RELEASE MOVED EARLIER/

             ALLIANCE PHARMACEUTICAL CORP. REPORTS RESULTS
             /FOLLOWING IS REPEAT OF RELEASE MOVED EARLIER/
    SAN DIEGO, Feb. 13 /PRNewswire/ -- The following was released today by Alliance Pharmaceutical Corp. (NASDAQ: ALLP):
         ALLIANCE PHARMACEUTICAL CORP. AND SUBSIDIARIES
            (Condensed Consolidated Balance Sheets)
                                          Dec. 31,         June 30,
                                            1991              1991
    Assets
    Current assets:
     Cash and cash equivalents          $16,036,000       $7,747,000
     Marketable securities               58,723,000        9,065,000
     Accounts receivable - net                7,000            6,000
     Inventories                            176,000           95,000
     Prepaid expenses and other           1,039,000          756,000
      Total current assets               75,981,000       17,669,000
     Property, plant and
      equipment - net                     6,209,000        5,378,000
     Other assets - net                  21,803,000       21,801,000
      Total                            $103,993,000      $44,848,000
     Liabilities & Stockholders' Equity
     Current liabilities:
      Accounts payable and
       accrued expenses                  $1,717,000       $1,872,000
     Current portion of long-term
      debt                                  518,000          154,000
     Total current liabilities            2,235,000        2,026,000
     Convertible subordinated notes            ---         8,000,000
     Long-term debt                         472,000          336,000
     Other                                  500,000          631,000
    Stockholders Equity:
     Preferred stock - par value
      $.01 per share; authorized
      5,000,000 shares; no shares issued
     Common stock - par value $.01
      per share; authorized 25,000,000
      shares; outstanding 18,379,269
      shares at Dec. 31, 1991;
      14,511,554 shares at June 30, 1991    184,000          145,000
     Additional paid-in capital         185,132,000      108,847,000
     Capital arising from acquisition
      of subsidiary                       1,544,000             ---
     Accumulated deficit                (85,502,000)     (74,251,000)
      Total                             101,358,000       34,741,000
    Less: Deferred compensation            (572,000)        (886,000)
     Stockholders' equity               100,786,000       33,855,000
      Total                            $103,993,000      $44,848,000
             ALLIANCE PHARMACEUTICAL CORP. AND SUBSIDIARIES
            Condensed Statements of Consolidated Operations
                              (Unaudited)
                                           Three Months Ended
                                               Dec. 31,
                                          1991               1990
      Revenues:
    Product revenues - net              $2,000                   $0
    License and research revenue       339,000              553,000
    Total                              341,000              553,000
      Operating Expenses:
    Research and development         5,702,000            3,273,000
    General and administrative
     (including goodwill
     amortization of $581,000 for
     both of the six months ended
     Dec. 31, 1991 and 1990)         1,434,000            1,410,000
    Total                            7,136,000            4,683,000
    Loss From Operations            (6,795,000)          (4,130,000)
      Other Income (Expense):
    Interest income and other          893,000              497,000
    Interest expense                  (111,000)            (213,000)
    Other income - net                 782,000              284,000
    Net loss                       ($6,013,000)         ($3,846,000)
    Net loss per share                  ($0.34)              ($0.27)
    Weighted average number of shares
     outstanding                    17,451,000           14,200,000
                                             Six Months Ended
                                                 Dec. 31,
                                          1991               1990
      Revenues:
    Product revenues - net              $5,000              $16,000
    License and research revenue       678,000              863,000
    Total                              683,000              879,000
      Operating Expenses:
    Research and development         9,834,000            6,414,000
    General and administrative
     (including goodwill
     amortization of $581,000 for
     both of the six months ended
     Dec. 31, 1991 and 1990)         2,998,000            3,100,000
    Total                           12,832,000            9,514,000
    Loss From Operations           (12,149,000)          (8,635,000)
      Other Income (Expense):
    Interest income and other        1,221,000              987,000
    Interest expense                  (323,000)            (436,000)
    Other income - net                 898,000              551,000
    Net loss                      ($11,251,000)         ($8,084,000)
    Net loss per share                  ($0.70)              ($0.57)
    Weighted average number of shares
     outstanding                    15,990,000           14,171,000
    -0-                       2/13/92
    /CONTACT: Stuart Gauld, VP Investor Relations of Alliance Pharmaceutical, 619-558-4300/
    (ALLP) CO:  Alliance Pharmaceutical Corp. ST:  California IN:  MTC SU:  ERN 809 02-13-92 14:01 EST AL-CH -- SD003 -- 9879 02/13/92 15:36 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 13, 1992
Words:595
Previous Article:A. P. GREEN ANNOUNCES FOURTH QUARTER RESULTS
Next Article:HBO & COMPANY DECLARES DIVIDEND
Topics:


Related Articles
SAN DIEGO, Nov. 6 /PRNewswire/ -- The following was released today by Alliance Pharmaceutical Corp. (NASDAQ: ALLP):
ALLIANCE PHARMACEUTICAL CORP. REPORTS RESULTS
ALLIANCE PHARMACEUTICAL REPORTS RESULTS
ALLIANCE PHARMACEUTICAL REPORTS RESULTS
ALLIANCE PHARMACEUTICALS ANNOUNCES RESULTS
ALLIANCE PHARMACEUTICALS ANNOUNCES RESULTS
ALLIANCE PHARMACEUTICALS ANNOUNCES RESULTS
ALLIANCE PHARMACEUTICALS ANNOUNCES RESULTS
ALLIANCE PHARMACEUTICAL CORP. ANNOUNCES FIRST QUARTER FINANCIAL RESULTS
Alliance Pharmaceutical Corp. Announces First Quarter Financial Results.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters